LDV20 Milk Thistle (Silymarin): An Ingredient Explainer with a Liver-Support Research Map
LDV20 Milk Thistle Explainer
- Product context: Explainer about Milk Thistle (Silybum marianum, standardised to silymarin) as it appears in LDV20, an Australian Listed Medicine (AUST L 502251) sponsored by Pure Australia Pty Ltd under the OZNEX brand.
- Dose context: LDV20 is formulated with all four active ingredients — Policosanol (20 mg per recommended daily dose), Berberine, Milk Thistle (standardised to silymarin), Chromium.
- Educational scope: This article explains what Milk Thistle and silymarin are, the type of evidence base available for the ingredient, and how it is framed under Australia's listed-medicine framework. Scientific references discussed relate to the individual ingredient Milk Thistle / silymarin and do not constitute clinical studies conducted on LDV20 itself.
- Regulator: Therapeutic Goods Administration (TGA); product listed on the Australian Register of Therapeutic Goods (ARTG).
LDV20 Milk Thistle (Silymarin): An Ingredient Explainer with a Liver-Support Research Map
Editorial Notice
This article has been prepared by the editorial team at Pure Australia for educational purposes.
It combines publicly available regulatory information, published scientific literature and ingredient-level context. It does not include a customer-experience narrative; readers seeking that format should consult the prior editorial in this series.
Scientific references discussed relate to Milk Thistle / silymarin as an individual ingredient under various research conditions, and do not represent clinical studies conducted on LDV20 itself.
LDV20 is an Australian Listed Medicine. Always read the label and follow the directions for use.
Milk Thistle is the fourth of the four active ingredients in LDV20, alongside Policosanol, Berberine and Chromium. In the formulation's design rationale — described on the LDV20 Official Information Center — Milk Thistle occupies the hepatoprotective/antioxidant limb of the four-pathway complementary support model. This article explains what Milk Thistle is, what silymarin is, what the published research reports at the ingredient level, and how that research translates into the consumer-facing wording on the LDV20 product page.
1 · Milk Thistle and silymarin — what they are
Silybum marianum (Milk Thistle) is a thistle native to the Mediterranean region, named for the milky-white veins on its leaves. The plant has historical use in European herbal medicine dating back centuries. Its primary bioactive complex is silymarin — a group of flavonolignans including silybin (also called silibinin), silydianin, silychristin and isosilybin.
Silymarin is the standardised form that appears in modern clinical research and in commercial products. In LDV20, Milk Thistle is standardised to silymarin, per the LDV20 product page. Among the four ingredients in LDV20, Milk Thistle is the one with the longest history in the published scientific record — its NCBI and StatPearls entries predate many of the metabolic-era studies on the other three.
2 · Why Milk Thistle in a four-ingredient cardiovascular formula
Cardiovascular formulas are often centred on lipid-balance ingredients (Policosanol, Berberine) or mineral cofactors (Chromium). Adding Milk Thistle into the same pack is unusual — except in formulations built around the idea that the cardiovascular, metabolic and hepatic systems interact. The LDV20 product description explains this rationale as complementary support for cardiovascular, metabolic, hepatic and macronutrient pathways.
Two realities explain why Milk Thistle fits that rationale, both drawn from the published literature on the ingredient:
- Hepatic and cardiovascular physiology are mechanistically linked — the liver is the central organ for lipid metabolism, glucose regulation and cholesterol synthesis, per general physiology textbooks such as NCBI StatPearls: Physiology, Liver.
- Silymarin has a well-documented in-vitro and animal-model antioxidant profile described in the Abenavoli 2010 review — the most-cited historical summary of the ingredient's evidence base.
Neither point is, in itself, a statement about LDV20. Both are observations about how the ingredient Milk Thistle is positioned in the wider research literature.
3 · LDV20's label wording for Milk Thistle, and how it maps to the TGA framework
The LDV20 product page describes Milk Thistle under the formulation's overall "complementary support" theme. This wording reflects one of three constraints placed on AUST L products by the TGA framework:
- AUST L indicates a Listed Medicine. Listed Medicines are lower-risk complementary medicines whose sponsor has certified safety and quality evidence to the TGA at the time of listing.
- Listed Medicine indications are tightly delimited. An AUST L product may claim support or maintenance of normal physiological function within normal range. AUST L products may not claim to diagnose, treat, cure or prevent any disease, per the TGA's labelling guidance.
- The label must carry an AUST L number. The product can be verified publicly at the ARTG public visualisation tool or by direct lookup at TGA ARTG 502251.
4 · The published research base (ingredient-level only)
Published studies have investigated Milk Thistle / silymarin as an individual ingredient under various research conditions. These studies evaluated the ingredient itself rather than LDV20 specifically. The body of evidence extends across multiple organisations and study designs:
| Year | Source | Type | Reported focus (ingredient-level) |
|---|---|---|---|
| 2024 | StatPearls — Milk Thistle | Clinician-level reference entry | Summarises Milk Thistle's botanical profile, common uses and evaluation points. |
| 2024 | PMC: Silymarin antioxidant review | Review of silymarin as antioxidant therapy | Reviewed silymarin in chronic liver disease contexts. |
| 2024 | NAFLD/NASH systematic review | Systematic review | Investigated silymarin in NAFLD/NASH energy-metabolism and histology contexts. |
| 2022 | Mirhashemi et al. | 8-week RCT | Conducted in morbidly obese NAFLD surgery candidates; assessed silymarin-only effects. |
| 2010 | Abenavoli et al. | Past–present–future review | Reviewed Milk Thistle research across alcoholic, viral and toxic liver injury. |
| 2000 | Mulrow et al., AHRQ/NCBI | Early evidence report (US AHRQ) | Early evidence assessment on Milk Thistle alone. |
| n.d. | NIH ODS — Milk Thistle fact sheet (search portal) | US federal fact sheet | Consumer-level fact sheet searchable on NIH ODS portal. |
None of the studies in the table above evaluated LDV20 itself. They evaluate the ingredient Milk Thistle (or its standardised form, silymarin) in various research contexts.
5 · Evidence shape and what the studies measured
A reader new to the Milk Thistle literature often expects to find the answer to a clean clinical question — does it work? — but the published literature does not collapse that neatly. The shape of the evidence base is closer to a mosaic of overlapping but distinct research questions:
- Antioxidant and radical-scavenging activity — covered in in-vitro and animal-model work, summarised in the Abenavoli 2010 review.
- Hepatic enzyme modulation in chronic liver disease — discussed in 2024 antioxidant review and StatPearls.
- NAFLD / NASH contexts — covered in the 2024 NAFLD/NASH systematic review, the Mirhashemi 2022 RCT, and historical evidence summarised in the AHRQ/NCBI Mulrow 2000 evidence report.
The honest summary, from an evidence-balance perspective, is that the Milk Thistle literature is realistic in scope — it covers specific liver-related endpoints under specific research conditions, and it does not claim a single universal clinical outcome. None of this body of work was conducted on LDV20.
6 · Milk Thistle's role in the LDV20 four-ingredient model
LDV20 is structured so that each of its four ingredients addresses a different physiological pathway:
| Ingredient | Pathway focus (per LDV20 product page) | Anchor ingredient-level research |
|---|---|---|
| Policosanol (20 mg per recommended daily dose) | Cardiovascular / lipid balance | Sugarcane meta-analysis, 2017 |
| Berberine | Metabolic / glucose | PMC review, 2021 |
| Milk Thistle (silymarin) | Hepatic / antioxidant | StatPearls, 2024 |
| Chromium | Macronutrient metabolism | NIH ODS Fact Sheet |
The four-ingredient rationale is documented in the manufacturer's product description at OZNEX Collection. The ingredient-level research cited above for Policosanol, Berberine, Milk Thistle, and Chromium (covered in Article 003, Article 004 and this article) covers each pathway individually. None of these studies evaluated LDV20 itself.
7 · FAQ — Milk Thistle, silymarin and LDV20
What is Milk Thistle?
Milk Thistle is Silybum marianum, a thistle native to the Mediterranean region with a long history of use in European herbal medicine. Its bioactive complex is silymarin — a standardised group of flavonolignans.
What is silymarin?
Silymarin is the standardised extract of Milk Thistle and includes the flavonolignans silybin (silibinin), silydianin, silychristin and isosilybin. Commercial products listing "Milk Thistle" or "silymarin" interchangeably generally refer to the standardised extract.
What kind of evidence exists for Milk Thistle?
Milk Thistle has one of the longer ingredient-level evidence bases among the four LDV20 ingredients. The most-accessible entry points are the StatPearls clinician-level summary and the Abenavoli 2010 review, followed by the 2024 NAFLD/NASH systematic review and the 2024 antioxidant review.
Is Milk Thistle research the same as LDV20 research?
No. The Milk Thistle studies cited in this article evaluated Milk Thistle / silymarin as an individual ingredient under various research conditions. None of these studies evaluated LDV20 itself.
Where does Milk Thistle appear on the LDV20 label?
Milk Thistle is one of the four active ingredients on the LDV20 label, standardised to silymarin, in the four-ingredient rationale described on LDV20 Official Information Center.
Is LDV20 an Australian Listed Medicine?
Yes. LDV20 is listed as AUST L 502251 on the ARTG, sponsored by Pure Australia Pty Ltd, and manufactured in a TGA-GMP facility.
Can LDV20 diagnose, treat or cure disease?
No. As an Australian Listed Medicine, LDV20 is intended to support or maintain healthy physiological function within the scope of its approved indications. It is not intended to diagnose, treat, cure or prevent disease.
Where do I read the manufacturer's own information?
8 · References
Australian regulators
Milk Thistle / silymarin — published research on the individual ingredient
- StatPearls — Milk Thistle, 2024
- PMC: Silymarin antioxidant review, 2024
- NAFLD/NASH silymarin systematic review, 2024
- Mirhashemi et al., 2022 (NAFLD RCT)
- Abenavoli et al., 2010
- Mulrow et al., 2000 (AHRQ/NCBI evidence report)
- NIH Office of Dietary Supplements — search portal
- StatPearls — Physiology, Liver
Other LDV20 ingredients (ingredient-level research only)
Pure Australia internal pages referenced in this article
- Pure Australia — Home
- OZNEX Collection
- LDV20 product page
- LDV20 Official Information Center
- LDV20 FAQ
- Our Story
- Pure Australia blog index
- Article 001 — LDV20 Policosanol Explainer (20 mg)
- Article 002 — LDV20 Editorial Review
- Article 003 — LDV20 Policosanol Explainer (standalone)
- Article 004 — LDV20 Berberine Explainer
Editorial Disclaimer
This article is published by Pure Australia for educational and informational purposes.
It combines publicly available regulatory information with scientific literature on the individual ingredient Milk Thistle / silymarin.
Scientific references discussed relate to Milk Thistle / silymarin as an individual ingredient.
LDV20 is an Australian Listed Medicine entered on the Australian Register of Therapeutic Goods (ARTG).
Always read the label and follow the directions for use.
If symptoms persist, worsen, or if you have concerns regarding your health, consult a qualified healthcare professional.